title: Ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid induces apoptosis and cell cycle arrest in CNE-2Z nasopharyngeal carcinoma cells.
abstract: Ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid (5F), a compound isolated from Pteris semipinnata L. (PsL), inhibits cell proliferation and induces cell apoptosis in several cancer lines. We found that 5F induced apoptosis and G2 phase cell cycle arrest in the CNE-2Z nasopharyngeal carcinoma (NPC) cells, accompanied by a decrease of NF-κB expression. 5F suppressed the viability of CNE-2Z cells in a time- and dose-dependent manner. 5F induced G2/M phase cell cycle arrest, but did not induce p21. Further analysis revealed that CNE-2Z cells harbored two p53 mutations. 5F treatment resulted in mitochondrial apoptosis, associated with increased Bax/Bcl-2 ratio, upregulation of cytochrome c in the cytosol, decreased NF-κB-p65 and increased IκB. Of note, 5F significantly sensitized CNE-2Z cells to cisplatin. 5F did not increase ROS, but reduced ROS production alone or in combination with cisplatin. Our data suggest that 5F is a potential anti-NPC drug for the development of single agent therapy and therapy in combination with cisplatin.
authors.affiliation: Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong Medical College, and Department of General Surgery, 422 Hospital of PLA, Zhanjiang, Guangdong 524023, PR China.
authors.forename: Kefeng
authors.initials: K
authors.lastname: Wu
authors.forename: Yi
authors.initials: Y
authors.lastname: Liu
authors.forename: Yingnian
authors.initials: Y
authors.lastname: Lv
authors.forename: Liao
authors.initials: L
authors.lastname: Cui
authors.forename: Wende
authors.initials: W
authors.lastname: Li
authors.forename: Jianfa
authors.initials: J
authors.lastname: Chen
authors.forename: Nian Ci
authors.initials: NC
authors.lastname: Liang
authors.forename: Li
authors.initials: L
authors.lastname: Li
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D001483:Base Sequence; D002277:Carcinoma; D045744:Cell Line, Tumor / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D004252:DNA Mutational Analysis; D004224:Diterpenes / Q000494:pharmacology*; D004357:Drug Synergism; D059565:G2 Phase Cell Cycle Checkpoints / Q000187:drug effects*; D006801:Humans; D020672:I-kappa B Proteins / Q000235:genetics / Q000378:metabolism; D008969:Molecular Sequence Data; D000072000:NF-KappaB Inhibitor alpha; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D017384:Sequence Deletion; D051996:Transcription Factor RelA / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000235:genetics; D015854:Up-Regulation
chemical_list: C479310:11-hydroxy-15-oxokaur-16-en-19-olic acid; D000972:Antineoplastic Agents, Phytogenic; D004224:Diterpenes; D020672:I-kappa B Proteins; C000606204:NFKBIA protein, human; D019253:Proto-Oncogene Proteins c-bcl-2; C498143:RELA protein, human; D017382:Reactive Oxygen Species; C495901:TP53 protein, human; D051996:Transcription Factor RelA; D016159:Tumor Suppressor Protein p53; D000072000:NF-KappaB Inhibitor alpha; D002945:Cisplatin
references.citation: Head Neck. 2010 Nov;32(11):1506-18
references.pmid: 20146336
references.citation: Cancer Lett. 2010 Sep 1;295(1):44-53
references.pmid: 20206442
references.citation: Med Oncol. 2011 Dec;28(4):1338-42
references.pmid: 20499210
references.citation: Apoptosis. 2005 Dec;10(6):1345-56
references.pmid: 16215682
references.citation: Curr Opin Cell Biol. 2004 Dec;16(6):670-8
references.pmid: 15530779
references.citation: FEBS Lett. 2005 Feb 28;579(6):1477-87
references.pmid: 15733860
references.citation: Clin Cancer Res. 2007 Feb 15;13(4):1076-82
references.pmid: 17317814
references.citation: Food Chem Toxicol. 2011 Aug;49(8):1737-44
references.pmid: 21554918
references.citation: Int J Oncol. 2011 Apr;38(4):1067-73
references.pmid: 21271215
references.citation: Invest New Drugs. 2012 Dec;30(6):2210-8
references.pmid: 22227815
references.citation: Oncol Rep. 2003 Nov-Dec;10(6):1663-82
references.pmid: 14534679
references.citation: Cancer Res. 1989 Apr 1;49(7):1671-5
references.pmid: 2538230
references.citation: Br J Cancer. 1997;76(2):206-10
references.pmid: 9231920
references.citation: Cancer Treat Rev. 2006 Aug;32(5):390-7
references.pmid: 16781082
references.citation: Mol Pharmacol. 2005 Sep;68(3):625-34
references.pmid: 15942022
references.citation: Biochem Pharmacol. 2007 May 1;73(9):1499-510
references.pmid: 17291459
references.citation: Cancer Res. 1987 Sep 1;47(17):4613-7
references.pmid: 3040227
references.citation: BMC Cancer. 2011 Jan 11;11:9
references.pmid: 21223552
references.citation: Carcinogenesis. 2012 Apr;33(4):810-7
references.pmid: 22301282
references.citation: Cell. 2009 May 1;137(3):413-31
references.pmid: 19410540
references.citation: Arch Toxicol. 2006 Feb;80(2):62-73
references.pmid: 16189662
references.citation: Cancer Cell. 2004 Sep;6(3):203-8
references.pmid: 15380510
references.citation: World J Gastroenterol. 2006 Jan 7;12(1):21-8
references.pmid: 16440412
references.citation: DNA Cell Biol. 2004 Nov;23(11):769-76
references.pmid: 15585135
references.citation: J Mol Med (Berl). 2010 Dec;88(12):1265-76
references.pmid: 20830463
references.citation: Exp Toxicol Pathol. 2009 May;61(3):223-42
references.pmid: 18986801
references.citation: Apoptosis. 2004 Sep;9(5):619-27
references.pmid: 15314290
references.citation: Mol Pharm. 2006 May-Jun;3(3):351-61
references.pmid: 16749867
references.citation: Cell. 1991 Oct 4;67(1):197-211
references.pmid: 1913817
references.citation: J Biol Chem. 1994 Jan 14;269(2):787-90
references.pmid: 8288625
references.citation: Oncogene. 2004 Apr 1;23(14):2507-22
references.pmid: 14676829
references.citation: Biol Pharm Bull. 2006 Dec;29(12):2436-41
references.pmid: 17142978
references.citation: Hear Res. 2007 Apr;226(1-2):157-67
references.pmid: 17113254
references.citation: Mol Cancer Ther. 2006 Feb;5(2):296-308
references.pmid: 16505103
references.citation: Chin J Cancer Res. 2012 Jun;24(2):109-15
references.pmid: 23358391
references.citation: Biochemistry. 1978 Jul 11;17(14):2746-54
references.pmid: 80227
references.citation: J Formos Med Assoc. 2004 Jul;103(7):496-510
references.pmid: 15318271
references.citation: J Pharmacol Exp Ther. 2003 Jun;305(3):1183-90
references.pmid: 12649298
references.citation: Bioessays. 1995 Jun;17(6):471-80
references.pmid: 7575488
references.citation: Chin J Cancer Res. 2012 Mar;24(1):1-8
references.pmid: 23359628
references.citation: Cancer Chemother Pharmacol. 2011 Jun;67(6):1299-312
references.pmid: 20734047
references.citation: Cancer Lett. 1995 Jul 13;93(2):193-200
references.pmid: 7621428
references.citation: Science. 1996 Dec 6;274(5293):1672-7
references.pmid: 8939849
references.citation: Cell. 1999 Jan 22;96(2):245-54
references.pmid: 9988219
references.citation: Nat Rev Cancer. 2009 Jun;9(6):400-14
references.pmid: 19440234